LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Lineage Cell Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.95−0.03 (-2.61%)
Close on Oct 19, 2026
- Market cap
- $249.13M
- P/E (TTM)
- –
- Dividend yield
- –
Lineage Cell Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenues [Member] | $943.00K | $1.58M | $6.26M | $3.54M | $2.53M | $1.27M | $2.48M | $3.39M | $1.10M | $1.19M | $1.64M | $957.00K | 88.2% | -62.8% |
| Upfront License Fees [Member] | $600.00K | $860.00K | $881.00K | $1.76M | $2.53M | $1.27M | $2.48M | $3.39M | $1.10M | $1.19M | $1.64M | $957.00K | 56.1% | -76.3% |
| Event Based Milestones and Other Collaborative Revenue [Member] | $343.00K | $715.00K | – | – | – | – | – | – | – | – | – | – | 32.1% | – |
| Royalties, License and Other Revenues [Member] | $126.00K | $150.00K | $345.00K | $137.00K | $233.00K | $232.00K | $390.00K | $393.00K | $310.00K | $257.00K | $449.00K | $289.00K | 11.8% | -45.9% |
| Other Collaborative Revenue [Member] | – | – | – | $1.78M | – | – | – | $0 | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Lineage Cell Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.